SPECT imaging in dementia

British Journal of Radiology

Volumn 80, Issue SPEC. ISS. 2, 2007, Pages

  Pimlott, S L ^a   Ebmeier, Klaus P ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 1H IMIDAZO[1,2 B]PYRAZOLE I 123; 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL) N (3 FLUOROPROPYL) NORTROPANE I 123; 3 (2 AZETIDINYLMETHOXY)PYRIDINE I 123; [2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; ACETYLCHOLINE; AMYLOID PROTEIN; CYSTEINE ETHYL ESTER TC 99M; FLUORODEOXYGLUCOSE F 18; HEXAMETHYLPROPYLENE AMINE OXIME TECHNETIUM TC 99M; IODOBENZOVESAMICOL I 123; IODODEXETIMIDE I 123; IODOQUINUCLIDINYL BENZILIC ACID I 123; IOFETAMINE I 123; IOFLUPANE; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE I 123; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE C 11; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE I 123; NEUROTRANSMITTER; RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; DIAGNOSTIC AGENT; RADIOLIGAND; TRACER;

ALZHEIMER DISEASE; BRAIN BLOOD FLOW; BRAIN PERFUSION; CHOLINERGIC SYSTEM; COST EFFECTIVENESS ANALYSIS; DEMENTIA; HUMAN; LEWY BODY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; METABOLISM; METHODOLOGY; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; SCINTISCANNING; CLINICAL ASSESSMENT; DIAGNOSTIC VALUE; NEUROIMAGING; NON INVASIVE PROCEDURE;

DEMENTIA; HUMANS; NEUROTRANSMITTER AGENTS; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 43549084581     PISSN: 00071285     EISSN: None     Source Type: Journal    
DOI: 10.1259/bjr/89285735     Document Type: Review

References (59)

1. Catafau AM. Brain SPECT in clinical practice. Part I: perfusion. J Nucl Med 2001;42:259-71.
2. Camargo EE. Brain SPECT in neurology and psychiatry. J Nucl Med 2001;42:611-23.
3. Fibiger HC. Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci 1991;14:220-3.
4. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-90.
5. Perry EK, Haroutunian V, Davis KL, Levy R, Lantos P, Eagger S, et al. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport 1994;5:747-9.
6. Tiraboschi P, Hansen LA, Alford M, Merdes A, Masliah E, Thal LJ, et al. Early and widespread cholinergic losses differentiate dementia with Lewy bodies from Alzheimer disease. Arch Gen Psychiatry 2002;59:946-51.
7. 123I]-4- iododexetimide, a potent muscarinic cholinergic receptor antagonist. J Med Chem 1989;32:1057-62.
8. Claus JJ, Dubois EA, Booij J, Habraken J, deMunck JC, vanHerk M, et al. Demonstration of a reduction in muscarinic receptor binding in early Alzheimer's disease using iodine-123 dexetimide single-photon emission tomography. Eur J Nucl Med 1997;24:602-8.
9. Boundy KL, Barnden LR, Katsifis AG, Rowe CC. Reduced posterior cingulate binding of I-123 iodo-dexetimide to muscarinic receptors in mild Alzheimer's disease. J Clin Neurosci 2005;12:421-5.
10. Piggott M, Owens J, O'Brien J, Paling S, Wyper D, Fenwick J, et al. Comparative distribution of binding of the muscarinic receptor ligands pirenzepine, AF-DX 384, (R,R)-I-QNB and (R,S)-I-QNB to human brain. J Chem Neuroanat 2002;24:211-23.
11. Weinberger DR, Jones D, Reba RC, Mann U, Coppola R, Gibson R, et al. A comparison of FDG PET and IQNB SPECT in normal subjects and in patients with dementia. J Neuropsychiatry Clin Neurosci 1992;4:239-48.
12. Wyper DJ, Brown D, Patterson J, Owens J, Hunter R, Teasdale E, et al. Deficits in iodine-labelled 3-quinuclidinyl benzilate binding in relation to cerebral blood flow in patients with Alzheimer's disease. Eur J Nucl Med 1993;20:379-86.
13. Sunderland T, Esposito G, Molchan SE, Coppola R, Jones DW, Gorey J, et al. Differential cholinergic regulation in Alzheimer's patients compared to controls following chronic blockade with scopolamine: a SPECT study. Psychopharmacology (Berl) 1995;121:231-41.
14. Brown D, Chisholm JA, Owens J, Pimlott S, Patterson J, Wyper D. Acetylcholine muscarinic receptors and response to anti-cholinesterase therapy in patients with Alzheimer's disease. Eur J Nucl Med Mol Imaging 2003;30:296-300.
15. Colloby SJ, Pakrasi S, Firbank MJ, Perry EK, Piggott MA, Owens J, et al. In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) (123)I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage 2006;33:423-9.
16. Wong DF, Brasic JR, Zhou Y, Gay O, Crabb AH, Kuwabara H, et al. Human imaging of alpha-4-beta-2 nicotinic acetylcholine receptors in vivo using (123)I5-IODO-A-85380. J Nucl Med 2001;42:S533.
17. Fujita M, Seibyl JP, Vaupel B, Tamagnan G, Early M, Zoghbi SS, et al. Whole-body biodistribution, radiation absorbed dose, and brain SPET imaging with [(123)I]5-I-A-85380 in healthy human subjects. Eur J Nucl Med 2002;29:183-190.
18. Fujita M, Ichise M, van Dyck CH, Zoghbi SS, Tamagnan G, Mukhin AG, et al. Quantification of nicotinic acetylcholine receptors in human brain using [(123)I]5-I-A-85380 SPET. Eur J Nucl Med Mol Imaging 2003;30:1620-9.
19. Mukhin AG, Gundisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, et al. 5-iodo-A-85380, an alpha-4-beta-2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol 2000;57:642-9.
20. Hashikawa K. Nicotinic acetylcholine receptor imaging for dementia. Int Congr Ser 2006;1290:144-9.
21. O'Brien JT, Colloby SJ, Pakrasi S, Perry EK, Pimlott SL, Wyper DJ, et al. Alpha4beta2 nicotinic receptor status in Alzheimer's disease using 123I-5IA-85380 single-photon-emission computed tomography. J Neurol Neurosurg Psychiatry 2007;78:356-62.
22. Terrière E, Sharman M, Donaghey C, Herrmann LL, Lonie JA, Strachan M, et al. α4-β2 nicotinic receptor binding with 5IA in Alzheimer's disease - methods of scan analysis. Neurochem Res (in press) 2007.
23. Kuhl DE, Minoshima S, Fessler JA, Frey KA, Foster NL, Ficaro EP, et al. In vivo mapping of cholinergic terminals in normal aging, Alzheimer's disease, and Parkinson's disease. Ann Neurol 1996;40:399-410.
24. 125I]-iodobenzovesamicol binding reflects cortical cholinergic deficiency induced by specific immunolesion of rat basal forebrain cholinergic system. Nucl Med Biol 2000;27:23-31.
25. Walker Z, Costa DC, Janssen AG, Walker RW, Livingstone G, Katona CL. Dementia with lewy bodies: a study of post-synaptic dopaminergic receptors with iodine-123 iodobenzamide single-photon emission tomography. Eur J Nucl Med 1997;24:609-14.
26. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 2002;73:134-40.
27. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004;61:919-25.
28. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee HK. Imaging of dopamine transporters in humans with technetium-99m TRODAT-1. Eur J Nucl Med 1996;23:1527-30.
29. Versijpt JJ, Dumont F, Van Laere KJ, Decoo D, Santens P, Audenaert K, et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol 2003;50:39-47.
30. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001;81:741-66.
31. Selkoe DJ. Imaging Alzheimer's amyloid. Nat Biotechnol 2000;18:823-4.
32. 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease. J Nucl Med 2006;47:748-54.
33. Jobst KA, Barnetson LP, Shepstone BJ. Accurate prediction of histologically confirmed Alzheimer's disease and the differential diagnosis of dementia: the use of NINCDS-ADRDA and DSM-III-R criteria, SPECT, X-ray CT, and Apo E4 in medial temporal lobe dementias. Oxford Project to Investigate Memory and Aging. Int Psychogeriatr 1998;10:271-302.
34. Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
35. Tatsch K, Asenbaum S, Bartenstein P, Catafau A, Halldin C, Pilowsky LS, et al. Procedure Guidelines for Brain Perfusion SPET using 99mTc-labelled Radiopharmaceuticals: European Association of Nuclear Medicine; 2001 October 4.
36. 123I-labelled dopamine transporter ligands. European Association of Nuclear Medicine; 2001.
37. Coleman RE, Dillehay GL, Gelfand MJ, Graham LS, Morton KA, Olsen JO, et al. Performance of single photon emission computed tomography (SPECT) brain perfusion imaging (ACR practice guideline). Washington: American College of Radiologists; 2002.
38. Frisoni GB, Scheltens P, Galluzzi S, Nobili FM, Fox NC, Robert PH, et al. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry 2003;74:1371-81.
39. Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol 2000;7:133-44.
40. Dougall N, Bruggink S, Ebmeier KP. Clinical use of SPECT in dementia - a quantitative review. In: Ebmeier KP, editor. SPECT in Dementia. Basel: Karger Verlag; 2003:4-37.
41. Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 2004;12:554-70.
42. Jones RG, Benbow S, Bullock R, Burns A, Dening T, Jolley D, et al. Forgetful but not forgotten: assessment and aspects of treatment of people with dementia by a specialist old age psychiatry service (Council Report CR119): Royal College of Psychiatrists; 2005.
43. Burns A, O'Brien J, Auriacombe S, Ballard C, Broich K, Bullock R, et al. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol 2006;20:732-55.
44. Anderson I, Booth J, Creaney B, Colledge N, Cunningham C, Fox N, et al. Management of patients with dementia - a national clinical guideline (SIGN Guideline 86). Edinburgh: Scottish Intercollegiate Guidelines Network; 2006.
45. Fairbairn A, Gould N, Kendall T, Ashley P, Bainbridge I, Bower L, et al. Dementia - supporting people with dementia and their carers in health and social care (NICE Guideline 42). London: National Institute for Health and Clinical Excellence, and Social Care Institute for Excellence; 2006.
46. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005;65:1863-72.
47. Vaamonde-Gamo J, Flores-Barragan JM, Ibanez R, Gudin M, Hernandez A. DaT-SCAN SPECT in the differential diagnosis of dementia with Lewy bodies and Alzheimer's disease. Rev Neurol 2005;41:276-9.
48. Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with lewy bodies: a comparison of clinical diagnosis, FP-CIT SPECT imaging and autopsy. J Neurol Neurosurg Psychiatry 2007;78:1176-81.
49. 1I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007;6:305-13.
50. CHMP. Committee for Medicinal Products for Human Use Post-Authorisation Summary of Positive Opinion for Datscan [243688]. London: European Medicines Agency; 2006.
51. Kronborg Andersen C, Cairns J. Cost-effectiveness of SPECT in diagnosing Alzheimer's Disease. In: Ebmeier KP, editor. SPECT in Dementia. Basel: Karger Verlag; 2003:115-25.
52. McMahon PM, Araki SS, Sandberg EA, Neumann PJ, Gazelle GS. Cost-effectiveness of PET in the diagnosis of Alzheimer disease. Radiology 2003;228:515-22.
53. Silverman DH, Gambhir SS, Huang HW, Schwimmer J, Kim S, Small GW, et al. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253-66.
54. Dougall N, Nobili F, Ebmeier KP. Predicting the accuracy of a diagnosis of Alzheimer's disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 2004;131:157-68.
55. Ebmeier KP, Darcourt J, Dougall NJ, Glabus MF, Herholz K, Koulibaly PM, et al. Voxel-based approaches in clinical imaging. In: Ebmeier KP, editor. SPECT in Dementia. Basel: Karger Verlag; 2003:72-85.
56. Herholz K, Schopphoff H, Schmidt M, Mielke R, Eschner W, Scheidhauer K, et al. Direct comparison of spatially normalized PET and SPECT scans in Alzheimer's disease. J Nucl Med 2002;43:21-6.
57. Scheidhauer K, Herholz K. Comparing HMPAO-SPECT and FDG-PET in Alzheimer's disease. In: Ebmeier KP, editor. SPECT in Dementia. Basel: Karger Verlag; 2003: 86-94.
58. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594-607.
59. van der Flier WM, Scheltens P. Use of laboratory and imaging investigations in dementia. J Neurol Neurosurg Psychiatry 2005;76 Suppl 5:v45-52.